The majority of the presentation focused on NLC an
Post# of 30028
(Total Views: 528)
Posted On: 06/22/2020 4:31:36 PM
The majority of the presentation focused on NLC and its
3 - 5 min patented 3C protease Rapid Detection IP.
TODOS is generating revenue
Will be able tobgive a forecasting on business & revenue in a few weeks once they get a better sense of repeat business.
CLIA Lab update - moving from Phase 1 to Phase 2.
Phase 1 was validation of tests, which that have on a number of tests they offer now.
They are validating more and will release that information once completed.
Also Phase 2 is moving beyond running self testing.
They are now running tests from outside sources.
He spoke about High-Throughput testing and the numbers on why that's important and how it can / could effect revenue
• Ability to run high-throughput COVID-19 testing (defined as 200 or greater tests per day) - to take advantage of higher reimbursement rates - $100 vs. $51.33 per test (non-high throughput)
He mentioned constituents often. I couldn't tell if he was speaking of general business or of there is a Gov't contract in there somewhere on a State or local level.
Things are speeding up Ex- US in . Brazil, Singapore and Malaysia.
Again, news should be coming in over the next weeks over that.
He sounded "excited" or quite interested in the possibilities of 3C and it's IP and is holding back & waiting on releasing news on revenue, more testing validations, EX-US business, new partnerships.
He mentioned some things that sound like partnership though EMOR Emwrald Sheild and it's businesses with Carrie Health, Bonsa and all the partnerships through them could be building an extensive network, but didn't give any specifics.
Aloha
3 - 5 min patented 3C protease Rapid Detection IP.
TODOS is generating revenue
Will be able tobgive a forecasting on business & revenue in a few weeks once they get a better sense of repeat business.
CLIA Lab update - moving from Phase 1 to Phase 2.
Phase 1 was validation of tests, which that have on a number of tests they offer now.
They are validating more and will release that information once completed.
Also Phase 2 is moving beyond running self testing.
They are now running tests from outside sources.
He spoke about High-Throughput testing and the numbers on why that's important and how it can / could effect revenue
• Ability to run high-throughput COVID-19 testing (defined as 200 or greater tests per day) - to take advantage of higher reimbursement rates - $100 vs. $51.33 per test (non-high throughput)
He mentioned constituents often. I couldn't tell if he was speaking of general business or of there is a Gov't contract in there somewhere on a State or local level.
Things are speeding up Ex- US in . Brazil, Singapore and Malaysia.
Again, news should be coming in over the next weeks over that.
He sounded "excited" or quite interested in the possibilities of 3C and it's IP and is holding back & waiting on releasing news on revenue, more testing validations, EX-US business, new partnerships.
He mentioned some things that sound like partnership though EMOR Emwrald Sheild and it's businesses with Carrie Health, Bonsa and all the partnerships through them could be building an extensive network, but didn't give any specifics.
Aloha
(3)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼